免疫检查点抑制剂致甲状腺损伤的诊治进展

doi:10.16150/j.1671-2870.2021.04.002

摘要/Abstract

中图分类号:

R730.5

顾卫琼. 免疫检查点抑制剂致甲状腺损伤的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 338-342.

参考文献 29

[1]	de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell, 2020,38(3):326-333. doi: S1535-6108(20)30365-2 pmid: 32750319
[2]	Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management[J]. Crit Care, 2017,21(1):89. doi: 10.1186/s13054-017-1678-1 URL
[3]	Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020,70(2):86-104. doi: 10.3322/caac.21596 URL
[4]	Kostine M, Chiche L, Lazaro E, et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge[J]. Rev Med Interne, 2017,38(8):513-525. doi: S0248-8663(17)30025-5 pmid: 28214182
[5]	Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review[J]. Clin Endocrinol (Oxf), 2016,85(3):331-339. doi: 10.1111/cen.13063 URL
[6]	Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016,44:51-60. doi: 10.1016/j.ctrv.2016.02.001 URL
[7]	Vita R, Guarneri F, Agah R, et al. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination[J]. Thyroid, 2014,24(2):390-394. doi: 10.1089/thy.2013.0170 URL
[8]	Maekura T, Naito M, Tahara M, et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer[J]. In Vivo, 2017,31(5):1035-1039.
[9]	Kobayashi T, Iwama S, Yasuda Y, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study[J]. J Endocr Soc, 2018,2(3):241-251. doi: 10.1210/js.2017-00432 pmid: 29600292
[10]	Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017,28(3):583-589. doi: 10.1093/annonc/mdw640 pmid: 27998967
[11]	Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018,109(11):3583-3590. doi: 10.1111/cas.13800 URL
[12]	Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017,102(8):2770-2780. doi: 10.1210/jc.2017-00448 pmid: 28609832
[13]	Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor thera-py in cancer patients[J]. Ophthalmic Plast Reconstr Surg, 2019,35(1):50-52. doi: 10.1097/IOP.0000000000001161 URL
[14]	Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects[J]. Retina, 2018,38(6):1063-1078. doi: 10.1097/IAE.0000000000002181 URL
[15]	Muir CA, Clifton-Bligh RJ, Long GV, et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment[J]. J Clin Endocrinol Metab, 2021,106(9):e3704-e3713.
[16]	Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017,5(1):95. doi: 10.1186/s40425-017-0300-z pmid: 29162153
[17]	Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020,6(1):38. doi: 10.1038/s41572-020-0160-6 pmid: 32382051
[18]	Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage Ⅲ melanoma[J]. N Engl J Med, 2018,378(19):1789-1801. doi: 10.1056/NEJMoa1802357 URL
[19]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. doi: 10.1200/JCO.2016.68.2005 URL
[20]	Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions[J]. Cancer Treat Rev, 2017,57:36-49. doi: 10.1016/j.ctrv.2017.05.003 URL
[21]	U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0[R/OL]. 2010-06-14[2021-07-12]. https://www.researchgate.net/profile/Masayuki-Watanabe-8/publication/263706737_An_original_scoring_system_for_predicting_postoperative_morbidity_after_esophagectomy_for_esop-hageal_cancer/links/560e5db508ae48337515ee75/An-ori-ginal-scoring-system-for-predicting-postoperative-morbidity-after-esophagectomy-for-esophageal-cancer.pdf.
[22]	Girotra M, Hansen A, Farooki A, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management[J]. JNCI Cancer Spectr, 2018,2(3):pky021. doi: 10.1093/jncics/pky021 URL
[23]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2019.
[24]	Arima H, Iwama S, Inaba H, et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society[J]. Endocr J, 2019,66(7):581-586. doi: 10.1507/endocrj.EJ19-0163 URL
[25]	Ntali G, Kassi E, Alevizaki M. Endocrine sequelae of immune checkpoint inhibitors[J]. Hormones (Athens), 2017,16(4):341-350.
[26]	中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J]. 中华内分泌代谢杂志, 2021,37(1):1-16.
[27]	Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(suppl_4):iv119-iv142.
[28]	Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients trea-ted with immune gheckpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385 pmid: 29442540
[29]	Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer, 2019,7(1):306. doi: 10.1186/s40425-019-0805-8 URL

免疫检查点抑制剂致甲状腺损伤的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王文涵, 夏蜀珺, 詹维伟. 长链非编码RNA ENST00000489676在超声评估甲状腺乳头状癌颈部淋巴结转移中的应用[J]. 诊断学理论与实践, 2022, 21(04): 514-519.
[2]	徐琛莹, 李嫣然, 倪晓枫, 徐上妍, 林青. 超声预测老年甲状腺乳头状癌患者颈部淋巴结转移的效能及相关超声征象分析[J]. 诊断学理论与实践, 2022, 21(03): 343-348.
[3]	赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[4]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下甲状腺功能亢进症和甲状腺功能减退症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 128-129.
[5]	杨田, 吉翔, 牛建梅, 孔晓晓, 吕明丽. 二维超声在产前胎儿胸腺发育评估中的应用[J]. 诊断学理论与实践, 2021, 20(05): 471-474.
[6]	王晓斐, 张秋蕊. 免疫检查点抑制剂致肺部不良反应的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 343-348.
[7]	况李君, 陶玲玲, 詹维伟, 李伟伟, 樊金芳, 周伟. 负压细针抽吸和毛细抽吸活检法穿刺洗脱液中甲状腺球蛋白测定在甲状腺乳头状癌淋巴结转移中的诊断价值比较[J]. 诊断学理论与实践, 2021, 20(04): 367-371.
[8]	周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[9]	杨一娴, 倪仲馨, 夏蜀珺, 周伟, 詹维伟. 多灶性与单灶性甲状腺乳头状癌的临床病理特征及超声表现的比较[J]. 诊断学理论与实践, 2021, 20(02): 168-172.
[10]	赖丽梅, 周建桥. 超声引导下射频消融术在甲状腺结节治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(02): 216-220.
[11]	李松涛, 杨大恒, 孙杭, 岳玉林, 张倩, 刘倩琦, 武苏, 马长艳. 甲状腺功能血清学指标结合超声检查在鉴别儿童毒性弥漫性甲状腺肿与慢性淋巴细胞性甲状腺炎中的价值[J]. 诊断学理论与实践, 2020, 19(06): 600-604.
[12]	林小云, 戚露月, 章振林, 岳华. 一个多发性内分泌腺瘤2A家系的临床特征与基因突变分析[J]. 诊断学理论与实践, 2020, 19(05): 481-486.
[13]	叶蕾, 李浩榕. 良恶性甲状腺结节的分子鉴别诊断进展[J]. 诊断学理论与实践, 2020, 19(04): 334-338.
[14]	周伟, 陈易来, 詹维伟. 细针穿刺洗脱液中甲状腺球蛋白检测在诊断分化型甲状腺癌淋巴结转移中的应用进展[J]. 诊断学理论与实践, 2020, 19(04): 339-343.
[15]	周伟, 侯怡卿, 詹维伟. 超声造影及超声弹性成像在良恶性甲状腺结节鉴别诊断中的应用进展[J]. 诊断学理论与实践, 2020, 19(04): 344-349.